Below please find the list of our upcoming Studies:
Study Medication | Study | Major Inc / Criteria | Sponsor | Study Title |
Budesonide/Albuterol metered dose inhaler | Asthma | •Age 4 years old and above • Diagnosis of Asthma for at least 1 year • Receiving asthma maintenance therapies • History of at least 1 severe asthma exacerbation within the last 12 months |
Avillion | A long-term, randomized, double-blind, multicenter, parallel-group, phase III study evaluating the efficacy and safety of PT027 compared to PT007 administered as needed in response to symptoms in symptomatic adults and children 4 years of age or older with asthma (Mandala) / AV003 |
Study | Study | Major Inc / Criteria | Sponsor | Study Title |
Asthma – Observational study | Asthma | • Age 18 years old and above • Diagnosis of severe asthma for at least 1 year • Currently receiving care from specialist physicians (eg, pulmonologists and/or allergists) at the Investigator’s or sub-investigator’s site • Uncontrolled asthma despite receiving high-dose ICS with additional controllers, or use FDA-approved monoclonal antibodies or systemic corticosteroids or other systemic immunosuppressants for the treatment of severe asthma |
AstraZeneca | A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States. |
Study Medication | Study | Major Inc / Criteria | Sponsor | Study Title |
PF 04965842, a JAK kinase inhibitor oral tablet | Atopic Dermatitis / Eczema | • Age 12 to <18 years old • Have a diagnosis of chronic atopic dermatitis for at least 1 year • Have symptoms of moderate to severe AD when you enter the study • Have not responded to topical medications or needed systemic therapy to control their AD |
Pfizer | A phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with hereditary angioedema. |
Study Medication | Study | Major Inc / Criteria | Sponsor | Study |
BCX7353, an oral tablet | Hereditary Angioedema (HAE) | • Age 12 years old and above • Have been diagnosed with HAE Type 1 or 2 • Have access to and take their own prescribed on-demand acute attack medications (either at home or in a medical setting) |
BioCryst | An open-label study to evaluate the long-term safety of daily oral BCX7353 in subjects with type I and II hereditary angioedema |
Study Name | Study Medication | Major Inc / Criteria | Sponsor | Study Title |
Hereditary Angioedema (HAE) – pediatric prophylactic treatment | Takhzyro (Lanadelumab), anti-plasma kallikrein monoclonal antibody injection | • Age between 2 and < 12 years old at the time of study enrollment • Have a confirmed diagnosis of Hereditary Angioedema type I or II • Have at least one HAE attack per three months |
Takeda / Shire | An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age |
Study Name | Study Medication | Major Inc / Criteria | Sponsor | Study Title |
Hereditary Angioedema (HAE) – acute treatment | CSL312, Factor XIIa antagonist monoclonal antibody injection | CSL Behring LLC | The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, treatment patterns and Health Outcomes of Individuals with Severe Asthma in the United States. |
Study Name | Study Medication | Major Inc / Criteria | Sponsor | Study Title |
Hereditary Angioedema (HAE) – observational study | • Diagnosis of HAE Type I or Type II • Ability to use a mobile device for data collection in the study |
Takeda / Shire | the EMPOWER study An observational, non-interventional, study of patients with hereditary angioedema in the United States and Canada (EMPOWER study) |
Study Name | Study Medication | Major Inc / Criteria | Sponsor | Study Title |
Hereditary Angioedema (HAE) | • Age 2 years old and above • Confirmed or suspected to have HAE |
CSL Behring LLC | SAIRB-18-0006 Genetic profiling for patients with hereditary angioedema |
Study Name | Study Medication | Major Inc / Criteria | Sponsor | Study Title |
Peanut Allergy – Investigator Initiated Study | • Age between 6 months to 17 years old • Peanut allergic subjects or healthy controls |
CSL Behring LLC |